期刊
INTERNATIONAL JOURNAL OF UROLOGY
卷 19, 期 9, 页码 836-844出版社
WILEY
DOI: 10.1111/j.1442-2042.2012.03052.x
关键词
competing-risks regression; prostatic neoplasms; mortality; prostatic neoplasms; therapy; radiotherapy; statistics and numerical data; United States; epidemiology
资金
- University of Montreal Health Centre Urology Specialists
- Fonds de la Recherche en Sante du Quebec
- University of Montreal Department of Surgery
- University of Montreal Health Centre (CHUM) Foundation
Objectives: To compare the mortality outcomes of radical prostatectomy and radiotherapy as treatment modalities for patients with localized prostate cancer. Methods: Our cohort consisted of 68 665 patients with localized prostate cancer, treated with radical prostatectomy or radiotherapy, between 1992 and 2005. Propensity-score matching was used to minimize potential bias related to treatment assignment. Competing-risks analyses tested the effect of treatment type on cancer-specific mortality, after accounting for other-cause mortality. All analyses were stratified according to prostate cancer risk groups, baseline Charlson Comorbidity Index and age. Results: For patients treated with radical prostatectomy versus radiotherapy, the 10-year cancer-specific mortality rates were 1.4 versus 3.9% in low-intermediate risk prostate cancer and 6.8 versus 11.5% in high-risk prostate cancer, respectively. Rates were 2.4 versus 5.9% in patients with Charlson Comorbidity Index of 0, 2.4 versus 5.1% in patients with Charlson Comorbidity Index of 1, and 2.9 versus 5.2% in patients with Charlson Comorbidity Index of =2. Rates were 2.1 versus 5.0% in patients aged 6569 years, 2.8 versus 5.5% in patients aged 7074 years, and 2.9 versus 7.6% in patients aged 7580 years (all P < 0.001). At multivariable analyses, radiotherapy was associated with less favorable cancer-specific mortality in all categories (all P < 0.001). Conclusions: Patients treated with radical prostatectomy fare substantially better than those treated with radiotherapy. Patients with high-risk prostate cancer benefit the most from radical prostatectomy. Conversely, the lowest benefit was observed in patients with low-intermediate risk prostate cancer and/or multiple comorbidities. An intermediate benefit was observed in the other examined categories.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据